INTRODUCTIONHepatitis C virus (HCV) infection is a common cause of chronic liver infection, affecting 170 million individuals worldwide. HCV genotype 2, one of six HCV genotypes, is the third most common genotype in the world and is the cause of 30% of chronic HCV hepatitis in Japan. Chronic HCV infection is a major cause of end‐stage liver disease and hepatocellular carcinoma (HCC). Sustained virological response assessed at 12 weeks posttreatment (SVR12) is associated with a lower rate of morbidity and mortality.Twenty‐four weeks treatment of patients with HCV genotype 2 infection with peg‐interferon (Peg‐IFN) and ribavirin (RBV) has historically yielded favorable SVR rates. However, the clinical application of Peg‐IFN‐based treatment is limited due to poor tolerability, especially in patients with liver cirrhosis. The introduction of the highly efficient direct‐acting antiviral (DAA) drug combination, together with minor side effects and oral use has facilitated the treatment of chronic HCV hepatitis. In 2015, sofosbuvir (SOF), a nucleotide NS5B polymerase inhibitor, with good resistance profile, was approved in Japan for the treatment of patients with HCV genotype 2 hepatitis. However, no report have evaluated predictors of DAA‐treatment efficacy or treatment‐related changes in predictors of early hepatocarcinogenesis, such as α‐fetoprotein (AFP) and liver stiffness
Journal of Medical Virology – Wiley
Published: Jan 1, 2018
Keywords: ; ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera